NMRA-215

July 27, 2026: Neumora Therapeutics, Inc. (NASDAQ: NMRA) reported favorable preclinical toxicology results for NMRA-215, a brain-penetrant oral NLRP3 inhibitor being developed for obesity and cardiometabolic disease. After a prior 13-week rat tox study had unexpected in-life adverse findings in 5 of 142 animals, Neumora initiated a for-cause audit that found discrepancies and critical audit observations. In a repeat 13-week rat toxicology study (162 animals), no unexpected in-life adverse findings were observed. Based on the audit observations, the repeat study, and previously completed 28-day rat, 28-day dog, and 13-week dog toxicology studies, the company believes the earlier adverse findings were not related to NMRA-215.

The company highlighted preclinical efficacy in a diet-induced obesity mouse model, including weight loss as monotherapy, additive weight loss with semaglutide, and improved peripheral cardiometabolic biomarkers. Neumora plans to submit an IND for NMRA-215 in 4Q 2026 and anticipates initiating a clinical study in 2026.